Triple-Drug cocktail aims to make inoperable liver cancer removable
NCT ID NCT06796803
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This study tests whether combining an immunotherapy drug (camrelizumab), a targeted therapy (rivoceranib), and liver-directed chemotherapy (HAIC) can shrink intermediate-to-advanced liver tumors enough to allow surgical removal. About 400 adults with potentially resectable hepatocellular carcinoma will be randomly assigned to receive the triple combination or just the two systemic drugs. The main goals are to see how many patients achieve a complete tumor removal with clear margins and how long they live without the cancer coming back.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC)
- What this could lead to
- If successful, this approach could shrink advanced liver tumors enough to allow surgical removal, potentially curing more patients who otherwise have limited options.
- What could go wrong
- This is a mid-stage trial, so the combination may not work better than standard therapy and could cause serious side effects from the immune system or chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 398 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Feb 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Signed Informed Consent Form (ICF) 2. Aged ≥18 years and ≤75 years at time of signing ICF 3. Documented diagnosis of HCC confirmed by histology/cytology or clinically 4. Patients with BCLC stage B (the sum of number of tumors and the maximum diameter of the largest tumor exceeding Up-to-7 criteria) and BCLC stage C without extrahepatic metastasis: ① tumors confined to one lobe (left, right, or middle lobe), or tumors in one lobe are present alongside a single tumor with diameter ≤5 cm or up to three tumors each with diameter ≤3 cm in the remaining lobes; ②No PVTT involving the contralateral liver lobe or reaching the superior mesenteric vein. And no tumor thrombus of the inferior vena cava reaching right atrium 5. Patients with recurrence following prior radical surgical resection must have undergone the initial surgery at least 5 years prior to study entry 6. At least one measurable lesion (per RECIST v1.1) untreated lesion 7. ECOG performance status of 0 or 1 8. Child-Pugh ≤7 score 9. Life expectancy ≥12 weeks 10. Adequate organ function 11. No prior anti-tumor systemic therapies for HCC Exclusion Criteria: 1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC 2. Other active malignant tumor except HCC within 5 years or simultaneously 3. Prior locoregional therapy (such as TACE、TAE、HAIC、TARE) 4. There is an absolute contraindication to HAIC 5. History of hepatic encephalopathy 6. Diffuse HCC, intrahepatic tumor burden \> 50% 7. PVTT reaching the superior mesenteric vein, and bilateral PVTT are present 8. Clinically significant ascites 9. Prior allogeneic stem cell or solid organ transplantation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Potentially resectable hepatocellular carcinoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, 150000, China
-
Zhongshan Hospital
RECRUITINGShanghai, Shanghai Municipality, 200000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.